Early February VC Tally: 6 Biotech Firms Raise $153.5m
This article was originally published in Scrip
Will biotechnology firms in 2016 keep up the momentum that resulted in a record-breaking $7.4bn in US venture capital raised by the industry last year? It's possible if early-stage funding keeps up January's brisk pace, but it's too soon to tell if February will be a boom or a bust.
You may also be interested in...
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
Investors were impressed by the company's broad-spectrum, IV and oral antifungal drug in a space where few treatment options exist; Phase II trials will start later this year.
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.